Notice of Annual General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting on Thursday 20 May 2021.
Notice of Extraordinary General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting (“EGM”) to be held on Thursday 29 April 2021.
Abliva has completed a directed new issue
Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”), a biopharmaceutical company in the clinical phase that develops drugs for the treatment of rare and serious primary mitochondrial diseas ...
Abliva investigates the prerequisites for carrying out a directed new issue
Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or the “Company”) a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, toda ...
Abliva reports completion of KL1333 Phase 1a/b study
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced the completion ...
Abliva AB Year-End Report January – December 2020
2020 summary
Abliva appoints Ellen Donnelly as new CEO as it enters a new stage in its development
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the Board ...
Abliva Announces Termination of License Agreement with Fortify Therapeutics
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the license agreement with Fortify Therapeutics, a wholly-owned subsidiary of BridgeBio, regarding a development of a local treatment for Leber’ ...
Ablivas KL1333 heading for phase II/III in 2021
Abliva can look back on an eventful year, which was marked by the strategy shift towards treatments for mitochondrial diseases made last year. Several important milestones have been passed - including ...
Abliva AB Interim Report January – September 2020
KL1333 is on its way to pivotal clinical study - Pivotal study planned for the second half of 2021
Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced it has received ...
Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces dosing in the f ...